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Objectives: To compare the concordance of ceftaroline MIC values by reference broth microdilution (BMD) and
Etest (bioMe´rieux, France) for MSSA and MRSA isolates obtained from PREMIUM (D372SL00001), a European mul-
ticentre study.
Methods: Ceftaroline MICs were determined by reference BMD and by Etest for 1242 MSSA and MRSA isolates
collected between February and May 2012 from adult patients with community-acquired pneumonia or compli-
cated skin and soft tissue infections; tests were performed across six European laboratories. Selected isolates
with ceftaroline resistance in broth (MIC .1 mg/L) were retested in three central laboratories to confirm their
behaviour.
Results: Overall concordance between BMD and Etest was good, with .97% essential agreement and .95%
categorical agreement. Nevertheless, 12 of the 26 MRSA isolates found resistant by BMD scored as susceptible
by Etest, with MICs ≤1 mg/L, thus counting as very major errors, whereas only 5 of 380 MRSA isolates found
ceftaroline susceptible in BMD were miscategorized as resistant by Etest. Twenty-one of the 26 isolates with
MICs of 2 mg/L by BMD were then retested twice by each of three central laboratories: BMD MICs of 2 mg/L
were consistently found for 19 of the 21 isolates. Among 147 Etest results for these 21 isolates (original plus
six repeats per isolate) 112 were .1 mg/L.
Conclusions: BMD and Etest have good overall agreement for ceftaroline against Staphylococcus aureus; never-
theless, reliable Etest-based discrimination of the minority of ceftaroline-resistant (MIC 2 mg/L) MRSA is
extremely challenging, requiring careful reading of strips, ideally with duplicate testing.
Introduction
Ceftaroline is a new cephalosporin with broad activity against
common Gram-positive and Gram-negative pathogens including
MRSA.1,2 It has proved superior to vancomycin plus aztreonam in
complicated skin and soft tissue infections (cSSTI) and to ceftriax-
one in community-acquired pneumonia (CAP).1 – 3 On the basis of
these trials, ceftaroline, administered as its fosamil ester, was
approved for treatment of these infections by the US FDA in
October 2010,4 and by the EMA in August 2012.5
EUCAST categorizes Staphylococcus aureus with ceftaroline
MICs of ≤1 mg/L as susceptible and those with MICs .1 mg/L
as resistant.6 This might present a detection challenge, because
the ‘tail’ of the ceftaroline MIC distribution for MRSA extends to
2 mg/L.7 It was shown previously that routine diagnostic labora-
tories, at least in the UK,8 are poorly able to distinguish isolates with
MICs .1 mg/L from more susceptible organisms using either disc
or gradient tests, though better discrimination was achieved
using discs in a study in Sweden.9 In the present analysis we com-
pare Etest versus standard broth microdilution (BMD) for ceftaroline
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MIC determination. Moreover, we sought to examine whether dis-
crimination of isolates with MICs of 2 mg/L was achieved with
these methods. This analysis was undertaken in the course of
PREMIUM (D372SL00001), a multicentre European survey that
evaluated the activity of ceftaroline.
Materials and methods
Clinical isolates
Consecutive clinical isolates from cSSTI and CAP in patients aged
≥18 years were collected from February to May 2012 at 58 laboratories
in: Belgium (10 sites), Italy (16), Portugal (6), Spain (15), Switzerland (2)
and the UK (9). For CAP, samples were taken from sputum, bronchoalveo-
lar lavage (BAL), tracheal/bronchial aspirate, bronchoscopic protected
brush specimen, blood culture or pleural fluid. For cSSTI, fine needle aspir-
ation puncture/biopsy was preferred, although good-quality swabs were
also permitted. Collected isolates were then sent to the central laboratory
in the corresponding country, along with information about the micro-
organism and the source patient, recorded in an electronic Case Report
Form. The study was approved by the Ethics Committee (ref. 336/1,
Ramo´n y Cajal University Hospital, Madrid, Spain).
Antimicrobial susceptibility testing
Organisms were tested for susceptibility to ceftaroline by BMD and Etest
(bioMe´rieux, France) at six central laboratories. Each of these laboratories
tested isolates from their respective countries using the same methods
and quality control S. aureus ATCC 25923 isolate. BMD MICs were
determined using Sensititre plates (ThermoFisher Scientific, UK) with
Mueller–Hinton broth, as indicated by both EUCAST and CLSI specifica-
tions.6,10,11 The concentration range for ceftaroline was 0.008–4 mg/L.
Etest had ceftaroline gradients from 0.002 and 32 mg/L, which were
used on Mueller–Hinton agar from the laboratories′ local suppliers. MICs
were analysed with respect to EUCAST criteria, with ≤1 mg/L considered
susceptible and MIC .1 mg/L resistant.6
Data analysis
S. aureus isolates with MIC values obtained by both methods were included
in the analysis. Etest MICs were rounded up to the next concentration of the
standard doubling dilution scale when necessary. Concordance criteria
included: essential agreement (EA) (i.e. agreement within one doubling
dilution between methods), categorical agreement (CA) (agreement as
susceptible or resistant), major errors (susceptible by BMD but resistant
by Etest) and very major errors (VMEs; resistant by BMD but susceptible
by Etest).12 MIC distributions were compared by regression of log MICs
using WHONET software.13
Repetitive study: selective retesting of clinical isolates
Initial analyses revealed MICs .1 mg/L by BMD for 26 MRSA isolates. To
confirm these values, 21 of these isolates were retested twice by both
methods at the three central laboratories in Italy, Spain and the UK,
with results recorded by different operators. The remaining five isolates
were not available for reanalysis. Additionally, two isolates with MIC
1 mg/L were also retested as controls.
Results
MIC agreement: BMD versus Etest
A total of 1242 S. aureus isolates (836 MSSA and 406 MRSA) were
tested by both methods. For MSSA, the MIC50/MIC90 by BMD was
0.25/0.25 mg/L (range ≤0.008–1 mg/L) and 0.25/0.25 mg/L by
Etest (range 0.008–1 mg/L). For MRSA, the corresponding values
were 0.5/1.0 mg/L (range 0.125–4 mg/L) and 0.5/1.0 mg/L (range
0.016–4 mg/L) by BMD and Etest, respectively. EA was 97.1% for
MSSA and 97.3% for MRSA, whereas CA was 100% for MSSA and
95.8% for MRSA. Rounded-up MICs by Etest were lower than by
BMD in 308 (24.8%) cases, higher in 150 (12.1%) cases and iden-
tical in 784 (63.1%) cases. MIC correlation across the MIC spec-
trum was r¼0.37 (MSSA) and r¼0.62 (MRSA) (Figure 1).
Error rates
All MSSA isolates were found susceptible by both BMD and Etest
(Table 1). Among MRSA isolates, 17/406 (4.2%) were counted as
resistant by Etest but susceptible by BMD or vice versa. Crucially,
among the 26 isolates found resistant by BMD, with MICs of
2 –4 mg/L, 12 were found susceptible (i.e. MIC ≤1 mg/L) by
Etest, equating to a very major error rate of 46.2%. The major
error rate (susceptible by BMD but resistant by Etest) was much
lower, at 5/380 cases (1.3%).
Repetitive study
To further examine reproducibility and discrimination for isolates
with raised MICs, we selected 21 isolates with MIC 2 mg/L and two
with MIC 1 mg/L by BMD in the original analysis (Table 1). These
were then retested twice in each of three different central labora-
tories, giving seven results per method per isolate in total (six in
the repetitive study plus the original data). Nineteen isolates
gave consistent MICs of 2 mg/L by BMD, irrespective of where
and when tested. Among the 147 corresponding Etest results
(7×21), 112 indicated resistance (MIC.1 mg/L) and 35 suscepti-
bility (MIC 1 mg/L). Only 2 of the 19 isolates with consistent broth
MICs of 2 mg/L had a majority of Etest results at 1 mg/L, though
17 had a majority of results≥1.5 mg/L, rounded to 2 mg/L. Nine of
the 19 had no results at 1 mg/L (Table 1).
Discussion
Ceftaroline is one of a very few broad-spectrum agents with a
spectrum including MRSA (the only others are tigecycline and
ceftobiprole), and it is important that laboratories are able to
test it reliably. Although automated systems or disc testing are
the routine methods of susceptibility testing in most diagnostic
laboratories, gradient strips such as Etest are widely used for low-
throughput, high-precision work, when a more precise estimate of
the MIC is sought.
This study was therefore designed to compare Etest and
standard BMD methods for ceftaroline MIC determination, and
sought to assess whether Etest could reliably detect S. aureus
isolates with MICs .1 mg/L, which count as resistant according
to EUCAST criteria,6 though as intermediate on CLSI and FDA
breakpoints.10 This detection is inherently challenging, as MICs
for these isolates are almost invariably 2 mg/L (as in 25/26
cases here, Figure 1), and they might represent the tail of a nor-
mal distribution for MRSA isolates with WT PBP2a protein,7
though recent whole-genome sequence analysis shows that iso-
lates with ceftaroline MICs of 2–4 mg/L often have amino acid
substitutions in the non-penicillin-binding domain of PBP2a.14
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Figure 1. Comparison of ceftaroline MICs by BMD and Etest for (a) MSSA and (b) MRSA (analysis is based on initial results and excludes those of retesting).
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Table 1. Variability of repeat tests across centres
Country
Original test
centre
Original BMD
test MIC result
Total number of tests with
described MIC by BMD in the
repetitive study
Final BMD
MIC value
Original Etest
MIC result
Number of tests with described MIC by Etest in
the repetitive study
Final Etest
MIC result0.25 0.5 1.0 2.0 0.19 0.25 0.38 0.5 0.75 1.0 1.5 2.0
Spain 3404–46 2 6 2 1 3 3 1
Spain 3408–14 1 4 2 0.5 0.5 2 2 2 0.5
Spain 3409–64 2 6 2 2 1 3 2 2
Spain 3411–33 1 2 4 2 1 2 2 2 1
Portugal 3502–106 2 6 2 1.5 4 2 2
Portugal 3502–115 2 6 2 1.5 2 4 2
Portugal 3503–14 2 4 2 1 0.75 2 4 1
Italy 3901–006 2 6 2 1 3 3 2
Italy 3901–049 2 6 2 1.5 4 2 2
Italy 3901–032 2 6 2 1 2 4 2
Italy 3907–006 2 6 2 1 5 1 1
Italy 3907–10 2 6 2 1.5 6 2
Italy 3907–48 2 6 2 1 2 4 2
Italy 3909–081 2 6 2 1.5 4 2 2
Italy 3909–154 2 6 2 2 1 5 2
Italy 3909–164 2 6 2 1.5 5 1 2
Italy 3909–206 2 6 2 1.5 2 4 2
Italy 3909–244 2 6 2 1 3 3 2
Italy 3914–023 2 6 2 1.5 6 2
Italy 3914–40 2 6 2 1 2 4 2
Italy 3920–004 2 6 2 2 2 4 2
Italy 3923–021 2 2 4 2 1 2 2 2 2
Italy 3920–045 2 6 2 1.5 4 2 2
A total of seven tests were carried out per isolate (original result plus six in the repetitive study). Tests were performed at the original centre shown and repeated twice at three central
laboratories in Spain, Italy and the UK. The mode was taken as the final MIC when results across tests differed by≤2 doubling dilutions, and the median if results differed by.2 dilutions.
An MIC .1 mg/L is resistant according to EUCAST criteria. MIC values are expressed in mg/L.
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Such substitutions are prevalent in, for example, South Korea,
China and Thailand.15
In general, agreement between Etest and BMD MIC results is
good, although there are some systematic biases toward higher
or (mostly) lower MICs by Etest for particular microorganism–
antibiotic combinations.16 – 19 In the current study, Etest returned
slightly lower MICs than BMD for S. aureus and, although EA and
CA between the two methods exceeded 95%, almost half (12/26,
46.2%) of the MRSA isolates found resistant by BMD were scored
as susceptible, with MICs of 1 mg/L, by Etest in the original testing.
These findings, which were based on pooled results from the six
national laboratories, led us to retest 23 isolates, 21 of them
with initial MICs of 2 mg/L by BMD, at three central laboratories.
Each site tested each isolate twice by each method, with different
staff scoring the Etest and broth results. BMD MICs of 2 mg/L were
found for 19 isolates in all repeats at all sites, supporting the view
that their resistance was ‘real’. For 17, Etest MICs of .1.5 mg/L
(2 mg/L after rounding) were obtained in a majority of the seven
tests performed per isolate. This experience suggests that, with
careful reading, it is possible to reduce the proportion of cases
where low-level ceftaroline resistance is missed by Etest, thus
decreasing potential VME results. Performance may also be
improved if multiple Etests are run per isolate, albeit at additional
cost of time and materials. Reproducibility of MIC values with gra-
dient tests from other manufacturers also showed no clear dis-
tinction between isolates with MIC results of 1 and 2 mg/L.19
In conclusion, ceftaroline achieves robust in vitro antibacterial
activity against the great majority of S. aureus from cSSTI and CAP
in the European countries surveyed. Nevertheless, MICs of 2 mg/L,
signifying resistance on EUCAST criteria or intermediate status on
CLSI and FDA criteria, are seen for a small minority of isolates by
BMD. Detection of these non-susceptible organisms by Etest is
challenging, even under reference laboratory testing, as here,
requiring experience and diligence on the part of the individual
reader. We cannot rule out heteroresistance and/or protein
amino acid substitutions in the non-penicillin-binding domain of
PBP2a of these isolates.14,15,20
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